Pharmaceutical Executive
The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .
Urs Wiedemann
Advertisement
Articles by Urs Wiedemann
Advertisement
Latest Updated Articles
Raising the Stakes On Value-Based PricingApril 12th 2016
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
3
What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?
4
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
5